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Regulation of integrin affinity and clustering plays a
key role in the control of cell adhesion and migration.
The protein ICAP-1 (integrin cytoplasmic domain-asso-
ciated protein-1) binds to the cytoplasmic domain of
the 1A integrin and controls cell spreading on fibronec-
tin. Here, we demonstrate that, despite its ability to
interact with 1A integrin, ICAP-1 is not recruited in
focal adhesions, whereas it is colocalized with the inte-
grin at the ruffling edges of the cells. ICAP-1 induced a
rapid disruption of focal adhesions, which may result
from the ability of ICAP-1 to inhibit the association of
1A integrin with talin, which is crucial for the assembly
of these structures. ICAP-1-mediated dispersion of 1A
integrins is not observed with 1D integrins that do not
bind ICAP. This strongly suggests that ICAP-1 action
depends on a direct interaction between ICAP-1 and
the cytoplasmic domain of the 1 chains. Altogether,
these results suggest that ICAP-1 plays a key role in
cell adhesion by acting as a negative regulator of 1
integrin avidity.
Interactions of cells with the extracellular matrix are essen-
tial for survival, differentiation, and proliferation of cells (1).
They are mainly mediated by type I  heterodimer transmem-
brane receptors named integrins (2). Integrin-mediated cell
adhesion is a highly controlled process that can be modulated
very rapidly by two mechanisms: the modulation of the recep-
tor affinity by a conformational change and the modulation of
receptor avidity by lateral diffusion and clustering into highly
ordered structures named focal adhesions. As shown for the
platelet integrin IIb3, the effects of integrin clustering and
affinity modulation are additive and seem to play complemen-
tary roles (3). The conformational change that modulates the
affinity of some integrins is mediated by monomeric G proteins
of the Ras family. R-Ras seems to prevent H-Ras-dependent
decrease in integrin affinity (4–6). However, proteins involved
in this signaling pathway are still largely unknown (6, 7).
On the other hand, it has been reported that intracellular
calcium plays a key role in cell adhesion (8). Calcium-depend-
ent cycles between high and low affinity states of integrins
seem to be crucial for cell migration (9–12). More recently, we
found that the affinity state of the 51 integrin in CHO
1 cells
may be switched by the balance between two antagonistic
enzymatic activities: calcineurin and calcium/calmodulin-de-
pendent protein kinase of type II (CaMKII) (13, 14). A CaMKII-
dependent inside-out signaling was also described as the mo-
lecular basis of the cross-talk between v3 and 51 (15).
Although this regulatory pathway remains to be unraveled,
calcineurin has been shown to control v3 and 51 integrin
affinity in neutrophils and CHO cells, respectively (16, 17).
Finally a complex between 1 integrin and CaMKII was ob-
served in breast cancer MCF-7 cells (18). Although the regula-
tion of integrin function may involve phosphorylation events on
the threonine doublet TT788–789 of the 1A chain (19) or on
the threonine triplet TTT758–760 of the 2 chain (20), these
phosphorylation sites do not seem to be directly linked to the
CaMKII-dependent control of integrin affinity. Therefore, it is
likely that this latter signaling pathway occurs via an interme-
diate regulatory protein. This hypothesis was further sup-
ported by the fact that ectopically expressed  cytoplasmic
domains have a dominant negative effect on integrin function,
suggesting that some control proteins are titrated by the over-
expression of  cytoplasmic tails (21, 22).
Integrin cytoplasmic domain-associated protein-1 (ICAP-
1) was identified in a yeast two-hybrid screen as a protein
specifically associated with the cytoplasmic domain of 1A in-
tegrins (23). This protein has two isoforms named  and  of
200 and 150 amino acids, respectively. ICAP-1 is expressed
throughout development and also in adult tissues (24).
ICAP-1 but not ICAP-1 interacts with the cytoplasmic tail of
the 1A chain in a manner that depends on the conserved
NPXY integrin motif (25). ICAP-1 contains a number of pu-
tative phosphorylation sites, including a phosphorylation motif
for the CaMKII around threonine 38. We could show that a
point mutation T38D (that mimics the phosphorylated form) or
T38A (which cannot be phosphorylated) in ICAP-1 and ex-
pression of the corresponding recombinant proteins reduced or
increased cell spreading on fibronectin, respectively. These
data suggest that phosphorylation of ICAP-1 on threonine 38
by CaMKII modulates 51 integrin function (13). A further
involvement of ICAP-1 in the regulation of 1 integrin func-
tion was suggested by experiments indicating that its overex-
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pression increases cell motility on a 1-dependent substrate
such as fibronectin (26).
In this report we show that ICAP-1, despite its ability to
interact directly and specifically with the 1 integrin cytoplas-
mic domain in vitro, was never observed in focal adhesions. In
addition, ICAP-1 could inhibit the interaction between talin
and the 1 cytoplasmic tail in vitro. Because talin recruitment
is a prerequisite for focal adhesion assembly (27, 28), we have
FIG. 1. Antibodies characterization and cellular localization of the protein ICAP-1. A, the proteins of a HeLa cell lysate in radioimmune
precipitation assay buffer were resolved by SDS-PAGE and transferred onto a polyvinylidene difluoride membrane. The protein ICAP-1 was detected
with polyclonal antibodies. B, Western blots of ICAP-1 protein in NIH3T3 cells, HeLa cells, CHO cells, GD-25 cells, and GD-25 cells transfected with
ICAP-1 cDNA. C, HeLa cells were cultured overnight on fibronectin, fixed, permeabilized, and processed for double immunofluorescence labeling. In
a, HeLa cells are stained using polyclonal antibodies directed against ICAP-1. In d, HeLa cells are stained with the same polyclonal antibodies directed
against ICAP-1, which has been incubated with the recombinant ICAP-1 protein to compete with the ICAP-1-specific labeling. In b and e, HeLa cells
are stained using a monoclonal antibody directed against vinculin. In c and f is shown the merged images of a with b and d with e, respectively. D,
ventral plasma membranes (VPM) from HeLa cells were isolated, and double labeling of ICAP-1 (a) and vinculin (b) was carried out with specific
primary antibodies. These results are representative of three independent experiments. Bar, 10 m.
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analyzed the effect of ICAP-1 on the organization of these
structures and showed that this protein was able to disorganize
focal adhesions in a manner dependent on its direct interaction
with the 1 cytoplasmic tail. These results strongly suggest
that ICAP-1 is a key regulator of cell adhesion mediated
through 1 integrin and focal adhesion dynamic by weakening
talin binding to the 1 integrin.
EXPERIMENTAL PROCEDURES
Antibodies—The anti-1 tail serum (anti cyto-1) was raised against
a synthetic peptide corresponding to the cytoplasmic domain of the 1
chain covalently coupled to keyhole limpet hemocyanin. Anti-talin
monoclonal antibody (8d4) was purchased from Sigma (St. Louis, MO).
The monoclonal antibody 9EG7 directed against the 1 subunit was
kindly supplied by Dr. D. Vestweber (Muenster, Germany). The mono-
clonal antibody 7E2 directed against the hamster 1 subunit was a
generous gift of Dr. R. Juliano (Chapel Hill, NC). Polyclonal antibody
directed against the human ICAP-1 protein was previously described
(13). Cyanin3-, Alexa-, or rhodamine-conjugated goat anti-mouse or
anti-rabbit from Molecular Probes (Eugene, OR) or Immunotech (Mar-
seille, France) were used as secondary antibodies.
Cells and Cell Culture—The murine NIH3T3, the hamster CHO, and
the human HeLa cell lines were grown in -minimal essential medium
supplemented with 10% fetal calf serum, 100 units/ml penicillin, and
100 g/ml streptomycin. The murine GD25, GD25-1A, and GD25-1D
were grown in Dulbecco’s modified Eagle’s medium supplemented with
10% fetal calf serum, 100 units/ml penicillin, and 100 g/ml streptomy-
cin. GD25 cells do not express the 1 integrin chain due to a null mutation
in both alleles (29). GD25 cells transfected with either the murine 1A, or
the human 1A and 1D full-length cDNA are called GD25-1A and
GD-1D, respectively, and have been described earlier (30, 31). All
transfected cells were grown in complete medium supplemented with
the appropriate antibiotics for the selection of the transfected cells.
Protein Purifications—ICAP-1 and ICAP-1 fragments fused to a
polyhistidine tag at the N-terminal position were purified from the
BL21(DE3) Escherichia coli strain containing the vector pET19b-ICAP-
1. Briefly, human ICAP-1 cDNA cloned in pBluescript was used as a
template in a PCR reaction using primers with an XhoI site in the 5
position. In the sense primer the XhoI site is in-frame with the first
methionine of ICAP-1. Then the XhoI-digested PCR product was
cloned into the XhoI site of pET-19b vector (Novagen). Fragments were
obtained by insertion of stop codons at different positions using the
QuikChange mutagenesis kit (Stratagene). All constructs used in this
study have been sequenced by the Eurogentec direct sequencing depart-
ment (Belgium). Purification was carried out using the nickel-charged
resin nickel-nitrilotriacetic acid from Qiagen. Inclusion bodies were
solubilized in urea. Protein refolding was performed directly on the
column by progressive removal of the chaotropic agent. The purity of
the protein was checked by SDS-PAGE and Coomassie Blue staining
and was greater than 90–95%. All experiments were carried out with
freshly purified proteins. Before each experiment, the capacity of each
batch of the purified protein to interact with the 1 cytoplasmic domain
was estimated in a solid-phase assay.
The polypeptide corresponding to the 1 integrin cytoplasmic domain
was produced from the BLR(DE3)pLysS E. coli strain containing the
vector pET19b-cyto1. This construct allows the production of the frag-
ment 752–798 of the 1 integrin cytoplasmic domain. This peptide was
recognized by a polyclonal antibody raised against a synthetic 1 cyto-
plasmic peptide coupled to keyhole limpet hemocyanin. Talin and -ac-
tinin were purified as previously described (32), and fibronectin was
purified according to a previous study (33).
Transfection in Mammalian Cells and Selection of Stable Clones—
Full-length human ICAP-1 was excised from the pBS-ICAP-1 vector
as an EcoRI/XbaI fragment and inserted into the pcDNA3.1() vector
(Invitrogen, The Netherlands). Stable GD25-1A cell lines expressing
ICAP-1 were obtained by electroporation of 4  106 cells in 400 l of
PBS at 280 V with 15 g of pcDNA3.1()-ICAP-1 vector. Transfected
cells were selected in complete medium with Zeocin (Invitrogen, The
Netherlands) at a final concentration of 300 g/ml. The expression of
ICAP-1 was monitored by indirect immunofluorescence and Western
blot analysis using the ICAP-1 polyclonal antibodies.
FIG. 2. ICAP-1 interacts specifically and directly with 1 inte-
grins. A, the capacity of ICAP-1 to interact with a peptide corresponding
to the 1 integrin cytoplasmic domain was checked in a solid-phase bind-
ing assay. A constant amount of purified recombinant ICAP-1 (10 g/
well) or BSA (3% w:v) was used to coat a 96-well tray overnight at 4 °C.
After a blocking step, increasing amounts of the wild type 1-cyto peptide
or YS 1-cyto mutant were added into the wells and detected with a
specific polyclonal antibodies. Each experimental point was obtained from
triplicate experiments, and background values of BSA coating have been
subtracted. These results are representative of three independent exper-
iments using different preparations of the purified ICAP-1 protein and
cyto-1 peptides. B, increasing amounts of the recombinant ICAP-1
protein were used to coat plastic wells of a 96-well tray. Subsequently, a
constant amount (300 g/well) of a CHO cell lysate was added. The 1
integrin receptors bound to ICAP-1were detected using the non-blocking
monoclonal antibody 7E2 (raised against the hamster 1 chain). The
results from three independent experiments using different preparations
of the purified ICAP-1 were averaged, and standard deviations are
shown. C, polyhistidine-tagged ICAP-1 fragments were used in the 1
binding assay described above. The wells were coated with 10 g of the
ICAP-1 recombinant fragments and then incubated with 300 g of CHO
cell lysate proteins. The bound 51 was immunodetected by the 7E2
anti-hamster 1 monoclonal antibody. Each histogram represents
mean  S.D. of three independent experiments.
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Immunofluorescence Microscopy—Immunofluorescence was carried
out using standard procedures. Stained cells were analyzed with an
inverted fluorescence microscope (Olympus Provis AX70) equipped with
a Plan Apo 63 oil immersion, numerical aperture 1.40 objective lens.
For all double-staining experiments, the appropriate controls were per-
formed to ensure that no undesired cross-reactivity occurred between
the primary and secondary antibodies.
Purification of Ventral Plasma Membranes—The purification of
HeLa, GD25-1, or NIH3T3 ventral plasma membranes was performed
as previously described by Cattelino et al. (34). The cells were grown
overnight on fibronectin-coated coverslips in complete medium. After
two washes in PBS, the cells were incubated with cold water for 2 min
and then flushed with a 1000-l tip. Cell disruption was confirmed by
microscopy. Ventral plasma membranes were either immediately fixed
with paraformaldehyde or were preincubated for 30 min at 4 °C with
ICAP-1 or ICAP-1 fragments at the concentration of 5 M in a VPM
buffer containing 125 mM potassium acetate, 2.5 mM MgCl2, 12 mM
glucose, and 25 mM HEPES, pH 7.5, prior to fixation.
Solid-phase Assays—The interaction between ICAP-1 and the
cyto-1 peptide or the whole 51 integrin was carried out using a
solid-phase assay. Briefly, a 96-well tray (MaxiSorp, Nunc) was coated
with the whole ICAP-1 protein or ICAP-1 fragments for 16 h at 4 °C
and blocked with a 3% BSA/PBS solution for 1 h at room temperature.
A Triton X-100 CHO cell lysate made in PBS supplemented with 1%
Triton X-100 (w:v) or the cyto-1 peptide were incubated for 1 h at 37 °C.
After three washes in PBS containing 3% BSA and 0.01% Tween-20,
detection of the 51 integrin from the CHO cell lysate was performed
using the 7E2 monoclonal antibody, whereas the detection of the cyto-1
peptide was achieved with a polyclonal antibody directed against a
synthetic peptide corresponding to the 1 tail.
Microinjection into NIH3T3 Cells—NIH3T3 cells were seeded onto
fibronectin-coated glass coverslips overnight at 37 °C. All injections
were carried out with the aid of a micromanipulator 5171 connected to
an Eppendorf microinjector unit (Transjector 5246). The cells were
microinjected with PBS containing a final concentration of 1 mg/ml of
the freshly purified recombinant ICAP-1 protein, or the N-terminal
(1–100) or C-terminal (101–200) fragments, in the presence of 100 M
tetramethylrhodamine-dextran amine (Mr 3000, Molecular Probes, In-
terchim, France) to view the injected cells. Three hours (whole ICAP-1
protein) or 30 min (ICAP-1 fragments) after microinjection, the cells
were fixed with 3% paraformaldehyde and 2% sucrose in PBS for 10 min
at 37 °C and then immunostained for vinculin localization.
RESULTS
ICAP-1 Does Not Localize in Focal Adhesions—The protein
ICAP-1 was isolated as a 1A-interacting protein in a yeast
two-hybrid screen (23) and was shown to modulate CHO cell
FIG. 3. Microinjection of purified
ICAP-1 causes focal adhesion disas-
sembly. NIH3T3 cells were seeded onto
fibronectin-coated coverslips and allowed
to spread overnight at 37 °C. Then a PBS
solution of dextran-rhodamine alone
(A–C) or supplemented with the purified
recombinant ICAP-1 protein at 1 mg/ml
(D–F), ICAP-1 1–100 fragment (G–I), or
ICAP-1 100–200 fragment (J–L), was
microinjected into the cells. After micro-
injection, the cells were fixed, permeabi-
lized as described under “Experimental
Procedures” and immunostained for vin-
culin. These panels are representative of
four independent experiments using dif-
ferent preparations of purified recombi-
nant ICAP-1 protein and fragments.
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adhesion (13) and to promote cell motility (26). In epithelial
cells or in cell lines derived from epithelial cells such as HeLa,
ICAP-1 could be detected in a cell lysate by Western blot using
a polyclonal antibody raised against the full-length recombi-
nant protein (Fig. 1A). The endogenous human ICAP-1 pro-
tein in HeLa cells migrates in SDS-PAGE like the ectopically
expressed protein in rodent fibroblast-like GD25 cells (Fig. 1B).
GD25, CHO, and NIH3T3 cells showed no detectable ICAP-1
expression as monitored by Western blot analysis. To deter-
mine the physiological relevance of the interaction between
ICAP-1 and the 1 integrin, we carried out immunomicros-
copy experiments of ICAP-1 in different cell lines. In HeLa
cells, ICAP-1 showed a diffuse expression pattern and often
some nuclear localization (Fig. 1C, panel a). Surprisingly, no
accumulation of ICAP-1 was observed in focal adhesions vi-
sualized by vinculin staining (Fig. 1C, panels a–c). Similarly,
we reported previously that in the Hs68 cell line, ICAP-1 and
1 colocalize in ruffles but not in focal adhesions (35). A direct
competition of endogenous ICAP-1 with the purified recombi-
nant protein revealed a dramatic decrease in ICAP-1 immu-
nostaining and confirmed the specificity of the immunolabeling
(Fig. 1C, panels d–f). Despite the diffuse ICAP-1 localization,
these cells were able to form well-organized focal adhesions
connected to stress fibers as judged by double labeling using a
monoclonal antibody directed against vinculin and phalloidin-
rhodamine-stained stress fibers (not shown).
To have direct access to focal adhesion proteins, ventral
plasma membranes were obtained from HeLa cells grown over-
night on fibronectin. Double immunostaining was performed
with an anti-vinculin antibody and anti-ICAP-1 polyclonal
antibodies. In these membrane preparations, focal adhesions
could be viewed by vinculin staining (Fig. 1D, panel b) or by
talin or 1 staining (not shown), whereas anti-ICAP-1 anti-
bodies showed a faint background staining that was barely
detectable (Fig. 1D, panel a). Altogether these results suggest
that ICAP-1 is not present in focal adhesions.
Interaction of ICAP-1 with the 51 Integrin—The absence
of ICAP-1 in focal adhesions prompted us to study the inter-
action of ICAP-1 with 1 integrins in more detail. ICAP-1
and the 1 cytoplasmic domains were expressed in bacteria as
polyhistidine fusion proteins. Fig. 2A shows that the purified
ICAP-1 protein interacted specifically with the purified 1
cytoplasmic domain in a solid-phase assay, which is consistent
with previous reports (23, 26). As a control, we used a 1
cytoplasmic domain bearing the point mutation Y to S in the
NPXY membrane distal (cyto3) domain. In full agreement with
a previous report (23), this mutation abolished the interaction
between ICAP-1 and the 1 cytoplasmic tail (Fig. 2A).
Next, we tested whether ICAP-1 was able to interact with
FIG. 4. ICAP-1 expression disrupts 1 integrin-containing fo-
cal adhesions. GD25-1A cells were stably transfected either with
vector alone (A and B) or with a cDNA coding for the full-length
ICAP-1 protein (C and D). Transfected cells were spread overnight at
37 °C on fibronectin-coated coverslips. The expression of ICAP-1 was
visualized with polyclonal antibodies (A and C) and the high affinity
conformational state of the 1 integrin with the 9EG7 monoclonal
antibody (B and D). Note that the reduction of 9EG7 staining correlated
with the expression of ICAP-1. Bar, 10 m.
FIG. 5. Purified ICAP-1 disrupts focal adhesions in vitro. Ven-
tral plasma membranes from NIH3T3 cells were prepared as described
under “Experimental Procedures.” The membranes were incubated at
4 °C for 30 min in the absence (A) or in the presence (B) of purified
recombinant ICAP-1 (5 M). Alternatively, the purified N-terminal
moiety of ICAP-1 (amino acids 1–100) shown in C or the C-terminal
moiety of ICAP-1 (amino acids 101–200) shown in D were added at a
concentration of 5 M. The membranes were subsequently fixed and
stained for vinculin. Note the dramatic reduction of vinculin staining
upon the addition of recombinant ICAP-1 or the C-terminal domain (B
and D). Photographs were taken with identical exposure times. These
observations are representative of four independent experiments using
different preparations of purified recombinant ICAP-1. Bar, 10 m.
FIG. 6. ICAP-1 integrin binding domain displaces 1A but not
1D integrins from focal adhesions. Ventral plasma membranes
from GD25-1A (A and C) and GD25-1D (B and D) cells were prepared
as described under “Experimental Procedures.” The membranes were
incubated at 4 °C for 30 min in the absence (A and B) or in the presence
(C and D) of the C-terminal moiety of ICAP-1 (amino acids 101–200)
added at a concentration of 5 M. The membranes were subsequently
fixed and stained for 1 integrins using the monoclonal antibody 4B7R.
Photographs were taken with identical exposure times. These observa-
tions are representative of four independent experiments using differ-
ent preparations of purified recombinant ICAP-1. Bar, 10 m.
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the whole 51 integrin from a CHO cell lysate. This was
crucial, because beta subunits do not exist in isolation in cells,
and therefore, two hybrid experiments with integrins may be
prone to artifacts. Increasing amounts of the recombinant
ICAP-1 protein were used to coat 96-well trays. The protein
concentration during coating was maintained constant by add-
ing BSA. An equal amount of a CHO cell lysate in Triton X-100
was subsequently incubated in each coated well. A dose-de-
pendent and -specific binding of the 1 integrin was detected by
a specific antibody (Fig. 2B). These data indicate that ICAP-1
expressed in bacteria is able to interact with the 1 cytoplas-
mic domain, and that the cytoplasmic domain of the  subunit
did not impair the interaction with ICAP-1.
Finally, we expressed ICAP-1 fragments in bacteria and
used them in a solid-phase binding assay to map the 1 binding
site. Only the C-terminal moiety (amino acids 100–200) of the
protein was able to bind to the 1 integrin (Fig. 2C). But neither
the fragment corresponding to amino acids 1–150 nor the frag-
ment corresponding to amino acids 151–200 of ICAP-1 were
found to interact strongly with the 51 integrin from cell
lysate (Fig. 2C).
ICAP-1 Disorganizes Focal Adhesions ex Vivo—Despite its
specific and direct association with the 1 integrin, ICAP-1
was not localized in focal adhesions. One possible explanation
for these contradictory results could be that ICAP-1 might act
as a negative regulator of the recruitment of focal adhesion
components. To investigate this possibility we microinjected
ICAP-1 recombinant protein into the cytoplasm of NIH3T3
cells and monitored focal adhesion organization by staining for
vinculin. Although microinjection of dextran-coupled rhoda-
mine alone had no significant effect on the localization of vin-
culin (Fig. 3, A–C), talin, and -actinin (not shown), microin-
jection of the full-length ICAP-1 in the dextran-coupled
rhodamine buffer induced a rapid delocalization of vinculin
(Fig. 3, D–F) or talin and -actinin (not shown) observed in 70%
of the cells. Microinjection of the C-terminal moiety of ICAP-1
(amino acids 101–200) that encompasses the 1 binding site
had similar effects (Fig. 3, J–L) in 77% of the injected cells.
Because the N-terminal fragment (amino acids 1–100) does not
bind the 1 integrin domain (Fig. 2C), we made use of this
recombinant fragment as a control. Indeed, the microinjection
of this part of ICAP-1 did not interfere with vinculin staining
(Fig. 3, G–I).
Finally, disruption of focal adhesions by ICAP-1 was also
investigated in a cellular context after stable transfection into
GD25-1A cells of a vector containing human ICAP-1 cDNA.
This cell line expresses functional 1 integrins at the cell sur-
face (19) that can be monitored by the 9EG7 monoclonal anti-
body, which recognizes a ligand-induced binding site epitope
correlating with the occupied conformational state of 1 inte-
grins (36, 37). Under our experimental conditions, immunoflu-
orescence microscopy did not reveal any detectable staining for
endogenous ICAP-1 in GD25-1A cells (Fig. 4A). On the other
hand, these cells exhibited surface expression of 1A integrins
confined to focal adhesions that could be monitored by the
9EG7 antibody (Fig. 4B). In a non-clonal population of GD25-
1A cells transfected with a cDNA encoding the human ICAP-
1, a positive immunofluorescence signal for ICAP-1 was dif-
fusely present within the cytoplasm (Fig. 4C). Simultaneously,
a diminution of cell spreading and loss of 9EG7 monoclonal
antibody staining was observed, suggesting that 1 integrins
were no longer occupied and involved in focal adhesions (Fig.
4D).
Disruption of Focal Adhesions by ICAP-1 Requires Direct
Interaction with the 1 Integrin Chain—The action of ICAP-1
on focal adhesions might be indirect, for instance due to the
interference with some regulatory pathways. Therefore, the
purified recombinant ICAP-1 was also tested for its ability to
disassemble focal adhesions in vitro in a cytosol-free ventral
plasma membrane preparation (VPM). These preparations are
depleted in nucleotide triphosphate and soluble signaling en-
zymes. The cell membranes were incubated for 30 min at 4 °C
with a solution of purified ICAP-1 in acetate buffer and glu-
cose. Although buffer alone did not interfere with the detection
of focal adhesion proteins such as vinculin (Fig. 5A), the incu-
bation with ICAP-1 efficiently displaced vinculin from focal
adhesions (Fig. 5B). A similar result was also observed for talin
FIG. 7. ICAP-1 competes with talin but not with -actinin
binding to the 1 cytoplasmic domain. A, increasing amounts of
purified recombinant ICAP-1 were preincubated with 1 g of the
cyto-1 peptide and then incubated in a 96-well tray coated with equal
amounts (10 g/well) of talin purified from human platelets. The bind-
ing of the cyto-1 peptide to talin was detected by polyclonal antibodies
raised against the cytoplasmic domain of the 1 integrin chain and a
biotin-conjugated anti rabbit secondary antibody. B, an amount of 2 g
of the recombinant protein ICAP-1 was preincubated with 1 g of the
cyto-1 peptide and incubated in 96-well plastic trays coated with 10 g
of purified talin (from human platelets) or -actinin (from chicken
gizzard). The binding of the cyto-1 peptide to talin or -actinin was
detected by polyclonal antibodies raised against the cytoplasmic do-
main of the 1 integrin chain and a biotin-conjugated anti-rabbit sec-
ondary antibody. C, a concentration of 1.5 g of ICAP-1 fragments
1–100 and 101–200 was preincubated with 1 g of the cyto-1 peptide
and incubated in 96-well plastic trays coated with 10 l of purified talin.
The binding of the cyto-1 peptide to talin was detected by polyclonal
antibodies raised against the cytoplasmic domain of the 1 integrin
chain and a biotin-conjugated anti rabbit secondary antibody. Each
experiment was performed in triplicate.
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and -actinin (not shown). The same result was obtained by the
incubation of the C-terminal part (amino acids 101–200) of
ICAP-1 (Fig. 5D). Finally, incubation of these ventral mem-
branes with the N-terminal purified fragment (amino acids
1–100) had no effect on focal adhesion organization (Fig. 5C).
ICAP-1 was suggested to have a GDP dissociating inhibitor
activity for Rac and Cdc42 (38), two monomeric G proteins of
the Rho family involved in the regulation of cytoskeleton orga-
nization. This activity might account for ICAP-1 destabilizing
action on focal adhesions of ventral plasma membranes. To
assess whether ICAP-1 action on focal adhesions was due to
its direct binding on 1 integrin chains or to some interference
with Rho signaling pathways, we performed similar experi-
ment on VPM from GD-251A and GD-251D cells lines. The
1D and 1A isoforms are functionally similar with regard to
integrin-mediated signaling (39), but the former strongly binds
talin (31) and does not bind ICAP-1 (38). Upon addition of the
ICAP-1 fragment 100–200, the dispersion of 1A integrins
initially clustered into focal adhesions was observed (Fig. 6, A
and C), whereas 1D-containing focal adhesions remained un-
affected (Fig. 6, B and D). This result strongly suggests that a
direct interaction between ICAP-1 and the 1 chain is a pre-
requisite for focal adhesion disassembly.
Talin and ICAP-1 Compete for Binding on the Cytosolic
Domain of the 1 Integrin Chain—Because talin interacts di-
rectly with the 1 integrin cytoplasmic domain and is crucial
for focal adhesion assembly, one attractive hypothesis is that
ICAP-1 is involved in the control of talin-integrin interaction.
Therefore, we tested whether ICAP-1 could modulate the
binding of talin to the integrin 1 cytoplasmic domain. In an in
vitro solid-phase assay, ICAP-1 could inhibit talin binding to
the cytoplasmic tail of the 1A chain in a dose-dependent man-
ner (Fig. 7A). These data suggest that the displacement of talin
from its binding site on 1A may be sufficient for focal adhesion
disruption and, consequently, for a decrease in the integrin
avidity. Moreover, the competition of ICAP-1 and talin for the
binding to 1 was specific, because it could not be observed
either with -actinin, another 1 interacting protein (Fig. 7B),
or with the 1–100 ICAP-1 moiety (Fig. 7C).
DISCUSSION
We examined the cellular localization of the endogenous
ICAP-1 protein. Surprisingly, this protein was never detected
in focal adhesions, but instead, exhibited a diffuse pattern
within the cell, although a significant amount of the protein
was associated within the Triton X-100-insoluble fraction (not
shown) and often, a nuclear staining was observed. Using pu-
rified ventral membrane preparation from HeLa cells, we never
observed ICAP-1 colocalized with vinculin or talin, which
were used as markers of focal adhesions.
Even though ICAP-1 was not detected in focal adhesions,
the purified recombinant protein interacted strongly with the
cytoplasmic domain of the 1A integrin chain as reported pre-
viously (23, 26). Additionally, this interaction also occurred
with the whole integrin receptors purified from a cell lysate.
The strong binding of ICAP-1 to the cytoplasmic domain of the
1 integrin and its complete absence from focal adhesions sug-
gested that this interaction may disrupt focal adhesion struc-
tures. To confirm this hypothesis we microinjected ICAP-1 in
NIH3T3 cells, and we indeed observed a rapid disorganization
of focal adhesions. In addition, recombinant ICAP-1 was able
to disaggregate focal adhesions when added to purified ventral
plasma membranes from NIH3T3 and GD-251A cells. Con-
versely, the 1D-containing integrins were resistant to ICAP-
1. This latter experiment strongly suggests that the disassem-
bly of focal adhesions is due to a direct interaction with the 1A
integrin subunit and is independent of a cellular signaling
pathway. Furthermore, the focal adhesion disruption mediated
by ICAP-1 is in good correlation with our previous data, which
have shown that ectopic expression of ICAP-1-regulated CHO
cell spreading (13).
Several reports have shown that talin is crucial for the for-
mation of focal adhesions (27, 28, 40). A simple explanation for
the negative effect of ICAP-1 on focal adhesion structure could
be its ability to disrupt the direct association between the
integrin and talin. To investigate this hypothesis we performed
an in vitro assay and found that talin and ICAP-1 compete for
binding to the 1A cytoplasmic domain. On the other hand, we
found that the interaction between -actinin and the 1 inte-
grin is not inhibited by the presence of ICAP-1. This shows
that ICAP-1 inhibits the interaction between 1A integrins
and talin in a specific manner and confirms previous reports
showing that the interaction of -actinin with the 1 cytoplas-
mic domain is not sufficient to stabilize focal adhesion sites
(40). The lack of effect of ICAP-1 on 1D localization suggests
that, under our experimental conditions, this action is direct
and not dependent on the GDP dissociating inhibitor activity
recently suggested (38). Based on these findings we propose
that ICAP-1 and talin compete for integrin 1A binding and
thereby modulate focal adhesion assembly and/or dynamic.
How ICAP-1 interferes with talin binding on the 1 integrin
needs further investigation. The talin binding site is not un-
ambiguously defined. Recent reports have demonstrated that
the talin N-terminal head binds to the 3, 1A, and 1D cyto-
plasmic domains (41, 42). Some data indicated that the binding
site of the talin head could be located on the proximal mem-
brane region of the integrin  chain (41). Conversely, other
reports indicate that a phosphotyrosine binding-like subdo-
main of the FERM domain of talin head is the major binding
site that triggers the activation of the IIb3 integrin (43). This
finding is very interesting, because it offers some molecular
basis of ICAP-1 and talin competition. Indeed, sequence ho-
mology and molecular modeling favor the view that ICAP-1 is
a phosphotyrosine binding domain protein. It was suggested
that the interaction specificity with the 1A cytosolic tail was
due to the interaction of Val-787 on the integrin and an hydro-
phobic pocket created by Leu-82 and Tyr-144 of ICAP-1 (25).
This is fairly consistent with the lack of interaction of ICAP-1
with the 1D isoform that do not have a valine at this position.
This latter residue is very close to the tyrosine 783 on the
human 1A chain. The tyrosine at this position on the 1 chain
or on the homologous position 747 on the 3 chain seems to be
crucial for integrin conformational switch and talin head bind-
ing. Moreover, talin C-terminal rod domain contains another
binding site located within the residues 1984–2541 (44). Be-
cause the talin-active form is an anti-parallel homodimer (32,
45), the head and tail integrin binding sites in the adjacent
talin molecules would be in close proximity with each other.
Therefore, it is likely that talin and ICAP-1 binding sites on
the integrin 1A tail overlap.
The distribution of ICAP-1 in ruffles and its absence from
focal adhesions suggest that the interaction between ICAP-1
and the 1 integrin cytoplasmic domain is regulated. It is
possible that ICAP-1 is sequestered inside the cell and that
the interaction between a sequestering protein and ICAP-1
may be the regulated event. Alternatively, the interaction of
ICAP-1 with the cytoplasmic domain of the 1 integrin may be
modulated by post-translational modifications (like phospho-
rylation). Indeed we have previously shown that a point muta-
tion into the CaMKII putative phosphorylation site dramati-
cally affected cell spreading (13). Moreover, pull-down assays
showed that only a small fraction of ICAP-1 was able to
interact with 1A (26). How the interaction of ICAP-1 and the
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integrin is regulated is not yet understood and requires further
investigations.
Recently, a 20-kDa protein named TAP-20 (with marked
homology with 3-endonexin) was shown to interact specifically
with the 5 cytosolic domain of the v5 integrin (46). Overex-
pression of this protein leads to decreased adhesion and focal
adhesion formation, and enhances migration. These properties
are quite reminiscent of those of ICAP-1, suggesting that a
family of negative regulators may control specific integrin
classes in a similar fashion.
Acknowledgments—We thank Dr. Frank Gertler for suggestions and
critical reading of the manuscript and Dr. R. Juliano and Dr. D. Vest-
weber for kindly providing monoclonal antibodies.
REFERENCES
1. Giancotti, F. G., and Ruoslahti, E. (1999) Science 285, 1028–1032
2. Hynes, R. O. (1992) Cell 69, 11–25
3. Hato, T., Pampori, N., and Shattil, S. J. (1998) J. Cell Biol. 141, 1685–1695
4. Hughes, P. E., Renshaw, M. W., Pfaff, M., Forsyth, J., Keivens, V. M.,
Schwartz, M. A., and Ginsberg, M. H. (1997) Cell 88, 521–530
5. Sethi, T., Ginsberg, M. H., Downward, J., and Hughes, P. E. (1999) Mol. Biol.
Cell 10, 1799–1809
6. Zhang, Z., Vuori, K., Wang, H., Reed, J. C., and Ruoslahti, E. (1996) Cell 85,
61–69
7. Keely, P. J., Rusyn, E. V., Cox, A. D., and Parise, L. V. (1999) J. Cell Biol. 145,
1077–1088
8. Sjaastad, M. D., and Nelson, W. J. (1997) Bioessays 19, 47–55
9. Bilato, C., Curto, K. A., Monticone, R. E., Pauly, R. R., White, A. J., and Crow,
M. T. (1997) J. Clin. Invest. 100, 693–704
10. Hendey, B., Klee, C. B., and Maxfield, F. R. (1992) Science 258, 296–299
11. Lawson, M. A., and Maxfield, F. R. (1995) Nature 377, 75–79
12. Pauly, R. R., Bilato, C., Sollott, S. J., Monticone, R., Kelly, P. T., Lakatta, E. G.,
and Crow, M. T. (1995) Circulation 91, 1107–1115
13. Bouvard, D., and Block, M. R. (1998) Biochem. Biophys. Res. Commun. 252,
46–50
14. Bouvard, D., Molla, A., and Block, M. R. (1998) J. Cell Sci. 111, 657–665
15. Blystone, S. D., Slater, S. E., Williams, M. P., Crow, M. T., and Brown, E. J.
(1999) J. Cell Biol. 145, 889–897
16. Hendey, B., Lawson, M., Marcantonio, E. E., and Maxfield, F. R. (1996) Blood
87, 2038–2048
17. Pomies, P., Frachet, P., and Block, M. R. (1995) Biochemistry 34, 5104–5112
18. Takahashi, K. (2001) BMC Cell Biol. 2, 23
19. Wennerberg, K., Fassler, R., Warmegard, B., and Johansson, S. (1998) J. Cell
Sci. 111, 1117–1126
20. Valmu, L., Hilden, T. J., van Willigen, G., and Gahmberg, C. G. (1999) Bio-
chem. J. 339, 119–125
21. Chen, Y. P., O’Toole, T. E., Shipley, T., Forsyth, J., LaFlamme, S. E., Yamada,
K. M., Shattil, S. J., and Ginsberg, M. H. (1994) J. Biol. Chem. 269,
18307–18310
22. Lukashev, M. E., Sheppard, D., and Pytela, R. (1994) J. Biol. Chem. 269,
18311–18314
23. Chang, D. D., Wong, C., Smith, H., and Liu, J. (1997) J. Cell Biol. 138,
1149–1157
24. Faisst, A. M., and Gruss, P. (1998) Dev. Dyn. 212, 293–303
25. Chang, D. D., Hoang, B. Q., Liu, J., and Springer, T. A. (2002) J. Biol. Chem.
277, 8140–8145
26. Zhang, X. A., and Hemler, M. E. (1999) J. Biol. Chem. 274, 11–19
27. Albiges-Rizo, C., Frachet, P., and Block, M. R. (1995) J. Cell Sci. 108,
3317–3329
28. Nuckolls, G. H., Romer, L. H., and Burridge, K. (1992) J. Cell Sci. 102, 753–762
29. Fassler, R., Pfaff, M., Murphy, J., Noegel, A. A., Johansson, S., Timpl, R., and
Albrecht, R. (1995) J. Cell Biol. 128, 979–988
30. Wennerberg, K., Lohikangas, L., Gullberg, D., Pfaff, M., Johansson, S., and
Fassler, R. (1996) J. Cell Biol. 132, 227–238
31. Belkin, A. M., Retta, S. F., Pletjushkina, O. Y., Balzac, F., Silengo, L., Fassler,
R., Koteliansky, V. E., Burridge, K., and Tarone, G. (1997) J. Cell Biol. 139,
1583–1595
32. Vignoud, L., Albiges-Rizo, C., Frachet, P., and Block, M. R. (1997) J. Cell Sci.
110, 1421–1430
33. Engvall, E., and Ruoslhati, E. (1977) Int. J. Cancer 20, 1–5
34. Cattelino, A., Longhi, R., and de Curtis, I. (1995) J. Cell Sci. 108, 3067–3078
35. Fournier, H. N., Dupe-Manet, S., Bouvard, D., Lacombe, M. L., Marie, C.,
Block, M. R., and Albiges-Rizo, C. (2002) J. Biol. Chem. 277, 20895–20902
36. Bazzoni, G., Shih, D. T., Buck, C. A., and Hemler, M. E. (1995) J. Biol. Chem.
270, 25570–25577
37. Lenter, M., Uhlig, H., Hamann, A., Jeno, P., Imhof, B., and Vestweber, D.
(1993) Proc. Natl. Acad. Sci. U. S. A. 90, 9051–9055
38. Degani, S., Balzac, F., Brancaccio, M., Guazzone, S., Retta, S. F., Silengo, L.,
Eva, A., and Tarone, G. (2002) J. Cell Biol. 156, 377–387
39. Belkin, A. M., Zhidkova, N. I., Balzac, F., Altruda, F., Tomatis, D., Maier, A.,
Tarone, G., Koteliansky, V. E., and Burridge, K. (1996) J. Cell Biol. 132,
211–226
40. Priddle, H., Hemmings, L., Monkley, S., Woods, A., Patel, B., Sutton, D., Dunn,
G. A., Zicha, D., and Critchley, D. R. (1998) J. Cell Biol. 142, 1121–1133
41. Patil, S., Jedsadayanmata, A., Wencel-Drake, J. D., Wang, W., Knezevic, I.,
and Lam, S. C. (1999) J. Biol. Chem. 274, 28575–28583
42. Calderwood, D. A., Zent, R., Grant, R., Rees, D. J., Hynes, R. O., and Ginsberg,
M. H. (1999) J. Biol. Chem. 274, 28071–28074
43. Calderwood, D. A., Yan, B., de Pereda, J. M., Alvarez, B. G., Fujioka, Y.,
Liddington, R. C., and Ginsberg, M. H. (2002) J. Biol. Chem. 277,
21749–21758
44. Xing, B., Jedsadayanmata, A., and Lam, S. C. (2001) J. Biol. Chem. 276,
44373–44378
45. Goldmann, W. H., Bremer, A., Haner, M., Aebi, U., and Isenberg, G. (1994) J.
Struct. Biol. 112, 3–10
46. Tang, S., Gao, Y., and Ware, J. A. (1999) J. Cell Biol. 147, 1073–1084
Control of Focal Adhesion by ICAP-16574
